This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter .

Today, a brief rundown of news involving Tenvie Therapeutics and Jasper Therapeutics, as well as updates from Sana Biotechnology, Stoke Therapeutics and City Therapeutics that you may have missed.

A new San Francisco-area startup, Tenvie Therapeutics , launched on Wednesday with $200 million in funding. Tenvie is supported by Arch Venture Partners, F-Prime Capital and Mubadala Capital, and is built around drug assets from another Arch-backed company, Denali Therapeutics . Tony Estrada , who oversaw drug discovery work at Denali for the better part of a decade, is now leading Tenvie. The company’s most advanced programs target two kinds of proteins tied to neurodegeneration. — Jacob Bell

Jasper Therapeutics on Wednesday shared data from a Phase 1b/2a study testing its antibody drug briquilimab in people with a type of hives known as chronic spontaneous urticaria. The company described the results as positive, showing treatment helped reduce hives severity and itchiness among study participants given one of six briquilimab doses. Jasper said treatment was well tolerated, but disclosed three people experienced neutropenia, including one whose adverse event was rated as medically significant. Investors appeared less impressed with the data, however, sending shares in the company down by more than half on Wednesday morning. — Ned Pagliarulo

Shares in Sana Biotechnology tripled in value Wednesday morning after the company said researchers using its technology successfully transplanted pancreatic islet cells into a person with Type 1 diabetes without using immunosuppression. According to Sana's CEO , this outcome is the first proof of an allogeneic transplant surviving without immune suppression or protection in an individual whose immune system is fully functioning. Researchers from Sweden's Uppsala University Hospital are conducting the study in partnership with Sana, which has developed a "hypoimmune" technology that can generate cells able to evade detection by the body's defenses. Sana is preparing to run its own study of an allogeneic islet cell therapy it's developing in-house for Type 1 diabetes. — Ned Pagliarulo

Stoke Therapeutics has finalized plans for a Phase 3 study testing its experimental drug for Dravet syndrome, a severe developmental disease characterized by regular seizures. According to the company, it secured "alignment" from regulators in the U.S., Europe and Japan to proceed with a one-year trial testing the effect of its drug on major motor seizure frequency. Stoke expects to enroll about 150 children and teenagers with Dravet in the trial, which it's dubbing Emperor. Data are expected by the end of 2027, the company said. — Ned Pagliarulo